A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects With Disability Following an Ischemic Stroke
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
At a glance
- Drugs ReN 001 (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms PISCES III
- Sponsors ReNeuron
- 24 Jan 2019 According to a ReNeuron media release, Sean I. Savitz MD (Professor and Director of the Institute for Stroke and Cerebrovascular Disease at the University of Texas Health Science Center at Houston (UTHealth)) is the global principal investigator for this study.
- 24 Jan 2019 According to a ReNeuron media release, top-line results from this study are expected in early 2020.
- 24 Jan 2019 According to a ReNeuron media release, the first patient has been treated in this phase IIb trial.